intravenous glutathione parkinson's disease randomized trial Revamping therapy using PLGA-based drug delivery systems Novel targeted therapies for Parkinson's
Description
[DOI] [PubMed] [Google Scholar] 87.Zweig JA, Brandes MS, Brumbach BH, et al
I., & Waheed, H
Binding of Antibody 2.1 Dilute antibody (Ab) to the final concentration of 5-50 g/mL with binding/wash buffer
The isolation was over
